Geron Corporation (GERN) has enrolled the first multiple myeloma patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in combination with other treatments.

The primary objective of the Phase I dose escalation study is to determine the safety, maximum tolerated dose (MTD) and objective response rate of GRN163L when administered intravenously in combination with bortezomib (Velcade(R) with and without dexamethasone in patients with relapsed or refractory disease.

I'm posting a link to this article because I think that it's important to keep an eye on new possible therapies.

http://www.newswise.com/articles/view/543775/?sc=mwhp 

"Researchers at The Wistar Institute have deciphered the
structure of the active region of telomerase, an enzyme that plays a
major role in the development of nearly all human cancers. The landmark
achievement opens the door to the creation of new, broadly effective
cancer drugs, as well as anti-aging therapies.